Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Nucl Med. 2016 Aug 4;58(1):162–168. doi: 10.2967/jnumed.116.177857

FIGURE 5.

FIGURE 5

Quantitative analysis of PET data and biodistribution of 89Zr-Df-Pembrolizumab in the PBL mouse model reconstituted with human peripheral blood mononuclear cells (PBMCs) and normal NSG mice. (A) PET ROI analysis is shown as time-activity curves of the blood, liver, spleen, kidneys, and muscle after intravenous injection of 89Zr-Df-Pembrolizumab in NSG mouse model (n=4). (B) PET ROI analysis is shown as time-activity curves of the blood, liver, spleen, kidneys, and muscle after intravenous injection of 89Zr-Df-Pembrolizumab in PBL mice (n=4). (C) Comparison of salivary gland uptake of 89Zr-Df-Pembrolizumab between NSG and PBL mice (n=4). (D) Biodistribution of 89Zr-Df-Pembrolizumab in the blood, organs, and tissues of NSG and PBL mice at 168 h post-injection (n=4). *p<0.05, **p<0.01.